Zydus Cadila has received final approval from the USFDA to market Propafenone Hydrochloride Extended-Release Capsules USP, 225 mg, 325 mg, and 425 mg (US RLD: Rythmol Capsules).
Propafenone is known as an anti-arrhythmic drug. It works by blocking the activity of certain electrical signals in the heart that can cause an irregular heartbeat.
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.
The group now has 315 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.
Also read:
Caplin gets USFDA nod for Neostigmine Methylsulfate Injection
Gilead gets USFDA nod to treat metastatic urothelial cancer
NATCO gets tentative USFDA nod for Ibrutinib tablets
First AI device to help detect colon cancer gets USFDA nod
Aleor gets tentative USFDA nod for drug for topical treatment
Zydus Cadila gets final USFDA nod for drug to treat High…
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
